文献速递肝病

非酒精性脂肪性肝病医生和患者病耻感的全球调查

Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
PubMed 文献 · J Hepatol · 2023-11-18

全球非酒精性脂肪性肝病(NAFLD)理事会开展横断面调查,覆盖23国1976例患者和25国825名医疗提供者。患者中48%曾向亲友披露病情,26%报告与超重/肥胖相关的病耻感,仅8%报告因NAFLD受歧视;38%提供者认为「脂肪性」一词有病耻感,42%认为更名为MASLD可能减少病耻感。

要点

  • 48%患者曾向亲友披露NAFLD/NASH,88%至少有时使用「脂肪肝」一词。
  • 26%患者报告与超重/肥胖相关的病耻感,仅8%报告因NAFLD受歧视。
  • 38%提供者认为「脂肪性」一词有病耻感,42%认为更名MASLD可能减少病耻感。

核心结论

  • NAFLD病耻感的认知在患者、提供者、地理区域和亚专科之间存在差异。
  • 医生与患者在病耻感及相关命名方面存在脱节。

研究设计与样本

  • 横断面研究,由全球NASH理事会创建两份调查:68项患者调查和41项提供者调查。
  • 患者调查完成1976例NAFLD患者,来自23个国家(51%中东/北非、19%欧洲、17%美国、8%东南亚、5%南亚)。
  • 提供者调查完成825名医疗提供者(67%为胃肠病学家/肝病学家),来自25个国家(39%中东/北非、28%东南亚、22%美国、6%南亚、3%欧洲)。

主要发现

  • 48%患者曾向家人/朋友披露患有NAFLD/NASH;最常用术语为「脂肪肝」(88%至少有时使用);「代谢性疾病」或「MAFLD」很少使用(从未使用比例>84%)。
  • 患者对各种诊断术语的感知无实质性差异,最常见反应为对术语既无不舒适也无舒适(56%-71%),美国和南亚患者对「FLD」稍感不适(47%-52%不适)。
  • 26%患者报告与超重/肥胖相关的病耻感,仅8%报告有因NAFLD受污名化或歧视的历史。
  • 38%提供者认为「脂肪性」一词有病耻感,34%认为「非酒精性」有病耻感,后者在中东/北非更常见(43%)。
  • 42%提供者认为更名为MASLD可能减少病耻感(胃肠病学家/肝病学家45% vs 其他专科37%,p=0.03);14%提供者认为「脂肪性肝病」有病耻感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with fatty liver disease may experience stigma from the disease or comorbidities. In this cross-sectional study, we aimed to understand stigma among patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) and healthcare providers. METHODS: Members of the Global NASH Council created two surveys about experiences/attitudes toward NAFLD and related diagnostic terms: a 68-item patient and a 41-item provider survey. RESULTS: Surveys were completed by 1,976 patients with NAFLD across 23 countries (51% Middle East/North Africa [MENA], 19% Europe, 17% USA, 8% Southeast Asia, 5% South Asia) and 825 healthcare providers (67% gastroenterologists/hepatologists) across 25 countries (39% MENA, 28% Southeast Asia, 22% USA, 6% South Asia, 3% Europe). Of all patients, 48% ever disclosed having NAFLD/NASH to family/friends; the most commonly used term was "fatty liver" (88% at least sometimes); "metabolic disease" or "MAFLD" were rarely used (never by >84%). Regarding various perceptions of diagnostic terms by patients, there were no substantial differences between "NAFLD", "fatty liver disease (FLD)", "NASH", or "MAFLD". The most popular response was being neither comfortable nor uncomfortable with either term (56%-71%), with slightly greater discomfort with "FLD" among the US and South Asian patients (47-52% uncomfortable). Although 26% of patients reported stigma related to overweight/obesity, only 8% reported a history of stigmatization or discrimination due to NAFLD. Among providers, 38% believed that the term "fatty" was stigmatizing, while 34% believed that "nonalcoholic" was stigmatizing, more commonly in MENA (43%); 42% providers (gastroenterologists/hepatologists 45% vs. 37% other specialties, p = 0.03) believed that the name change to metabolic dysfunction-associated steatotic liver disease (or MASLD) might reduce stigma. Regarding the new nomenclature, the percentage of providers reporting "steatotic liver disease" as stigmatizing was low (14%). CONCLUSIONS: The perception of NAFLD stigma varies among patients, providers, geographic locations and sub-specialties. IMPACT AND IMPLICATIONS: Over the past decades, efforts have been made to change the nomenclature of nonalcoholic fatty liver disease (NAFLD) to better align with its underlying pathogenetic pathways and remove any potential stigma associated with the name. Given the paucity of data related to stigma in NAFLD, we undertook this global comprehensive survey to assess stigma in NAFLD among patients and providers from around the world. We found there is a disconnect between physicians and patients related to stigma and related nomenclature. With this knowledge, educational programs can be developed to better target stigma in NAFLD among all stakeholders and to provide a better opportunity for the new nomenclature to address the issues of stigma.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Alqahtani SA, Alswat K, et al. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2023. PMID: 37984709. doi:10.1016/j.jhep.2023.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。